171 related articles for article (PubMed ID: 20380889)
1. Increased leukotriene E4 excretion in systemic mastocytosis.
Butterfield JH
Prostaglandins Other Lipid Mediat; 2010 Jun; 92(1-4):73-6. PubMed ID: 20380889
[TBL] [Abstract][Full Text] [Related]
2. The measurement of leukotrienes in urine as diagnostic option in systemic mastocytosis.
Raithel M; Zopf Y; Kimpel S; Naegel A; Molderings GJ; Buchwald F; Schultis HW; Kressel J; Hahn EG; Konturek P
J Physiol Pharmacol; 2011 Aug; 62(4):469-72. PubMed ID: 22100848
[TBL] [Abstract][Full Text] [Related]
3. Increased urinary leukotriene E4 and eosinophil protein X excretion in patients with interstitial cystitis.
Bouchelouche K; Kristensen B; Nordling J; Horn T; Bouchelouche P
J Urol; 2001 Dec; 166(6):2121-5. PubMed ID: 11696719
[TBL] [Abstract][Full Text] [Related]
4. Urinary 11β-PGF2α and N-methyl histamine correlate with bone marrow biopsy findings in mast cell disorders.
Divekar R; Butterfield J
Allergy; 2015 Oct; 70(10):1230-8. PubMed ID: 26095439
[TBL] [Abstract][Full Text] [Related]
5. Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production.
Butterfield JH; Weiler CR
Int Arch Allergy Immunol; 2008; 147(4):338-43. PubMed ID: 18622141
[TBL] [Abstract][Full Text] [Related]
6. Urinary leukotriene E4 and 9 alpha, 11 beta-prostaglandin F concentrations in mild, moderate and severe asthma, and in healthy subjects.
Misso NL; Aggarwal S; Phelps S; Beard R; Thompson PJ
Clin Exp Allergy; 2004 Apr; 34(4):624-31. PubMed ID: 15080817
[TBL] [Abstract][Full Text] [Related]
7. Survey of Mast Cell Mediator Levels from Patients Presenting with Symptoms of Mast Cell Activation.
Butterfield JH
Int Arch Allergy Immunol; 2020; 181(1):43-50. PubMed ID: 31722348
[TBL] [Abstract][Full Text] [Related]
8. Survey of aspirin administration in systemic mastocytosis.
Butterfield JH
Prostaglandins Other Lipid Mediat; 2009 Apr; 88(3-4):122-4. PubMed ID: 19429499
[TBL] [Abstract][Full Text] [Related]
9. Tryptase detection in bone-marrow blood: a new diagnostic tool in systemic mastocytosis.
Proelss J; Wenzel J; Ko Y; Bieber T; Bauer R
J Am Acad Dermatol; 2007 Mar; 56(3):453-7. PubMed ID: 17317486
[TBL] [Abstract][Full Text] [Related]
10. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms.
Alvarez-Twose I; González de Olano D; Sánchez-Muñoz L; Matito A; Esteban-López MI; Vega A; Mateo MB; Alonso Díaz de Durana MD; de la Hoz B; Del Pozo Gil MD; Caballero T; Rosado A; Sánchez Matas I; Teodósio C; Jara-Acevedo M; Mollejo M; García-Montero A; Orfao A; Escribano L
J Allergy Clin Immunol; 2010 Jun; 125(6):1269-1278.e2. PubMed ID: 20434205
[TBL] [Abstract][Full Text] [Related]
11. Increased production of cysteinyl leukotrienes and prostaglandin D2 during human anaphylaxis.
Ono E; Taniguchi M; Mita H; Fukutomi Y; Higashi N; Miyazaki E; Kumamoto T; Akiyama K
Clin Exp Allergy; 2009 Jan; 39(1):72-80. PubMed ID: 19128354
[TBL] [Abstract][Full Text] [Related]
12. Clinical course and urinary eicosanoids in patients with aspirin-induced urticaria followed up for 4 years.
Setkowicz M; Mastalerz L; Podolec-Rubis M; Sanak M; Szczeklik A
J Allergy Clin Immunol; 2009 Jan; 123(1):174-8. PubMed ID: 18842291
[TBL] [Abstract][Full Text] [Related]
13. The Utility of Measuring Urinary Metabolites of Mast Cell Mediators in Systemic Mastocytosis and Mast Cell Activation Syndrome.
Butterfield J; Weiler CR
J Allergy Clin Immunol Pract; 2020 Sep; 8(8):2533-2541. PubMed ID: 32142966
[TBL] [Abstract][Full Text] [Related]
14. Biochemical markers predictive for bone marrow involvement in systemic mastocytosis.
Donker ML; van Doormaal JJ; van Doormaal FF; Kluin PM; van der Veer E; de Monchy JG; Kema IP; Kluin-Nelemans HC
Haematologica; 2008 Jan; 93(1):120-3. PubMed ID: 18166795
[TBL] [Abstract][Full Text] [Related]
15. Increased Excretion of Mast Cell Mediator Metabolites During Mast Cell Activation Syndrome.
Butterfield JH
J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2542-2546. PubMed ID: 36863614
[TBL] [Abstract][Full Text] [Related]
16. Mast Cell Mediators of Significance in Clinical Practice in Mastocytosis.
Butterfield JH; Ravi A; Pongdee T
Immunol Allergy Clin North Am; 2018 Aug; 38(3):397-410. PubMed ID: 30007459
[TBL] [Abstract][Full Text] [Related]
17. Comparison of serum tryptase and urine N-methylhistamine in patients with suspected mastocytosis.
van Toorenenbergen AW; Oranje AP
Clin Chim Acta; 2005 Sep; 359(1-2):72-7. PubMed ID: 15913591
[TBL] [Abstract][Full Text] [Related]
18. Increases in urinary 9alpha,11beta-prostaglandin f2 indicate mast cell activation in wine-induced asthma.
Misso NL; Aggarwal S; Thompson PJ; Vally H
Int Arch Allergy Immunol; 2009; 149(2):127-32. PubMed ID: 19127069
[TBL] [Abstract][Full Text] [Related]
19. Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11β-prostaglandin2α.
Ravi A; Butterfield J; Weiler CR
J Allergy Clin Immunol Pract; 2014; 2(6):775-8. PubMed ID: 25439370
[TBL] [Abstract][Full Text] [Related]
20. Analytical and clinical validation of an LC-MS/MS method for urine leukotriene E4: A marker of systemic mastocytosis.
Lueke AJ; Meeusen JW; Donato LJ; Gray AV; Butterfield JH; Saenger AK
Clin Biochem; 2016 Sep; 49(13-14):979-82. PubMed ID: 26908217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
